India holds the world’s most untapped venom library. We’re decoding it with AI.
Millions of venom-derived molecules evolved to hit biological targets with high potency and selectivity.
We combine venomics, multi-omics, machine learning, and high-throughput screening to identify therapeutic leads.
Anchored in India’s extraordinary venom biodiversity and deep toxinology expertise.
"Venom peptides don't destroy.
They Bind, Block, Modulate"
Venoms are among nature’s most powerful molecular innovation systems. Across hundreds of millions of years, venomous animals have evolved molecules that act on the nervous system, cardiovascular system, immune system, metabolism, coagulation, and cellular signalling.
These molecules are valuable because they are:
Several important medicines were discovered from, or inspired by, venom and venom-associated molecules. These examples show that venom biology can produce clinically validated therapeutic mechanisms.
Derived from cone snail Conus magus toxin ω-conotoxin. A pioneering non-opioid analgesic for severe chronic pain.
Conus magus · FDA Approved 2004
Based on exendin-4 from Gila monster Heloderma suspectum saliva. The foundational GLP-1 receptor agonist for type 2 diabetes.
Heloderma suspectum · FDA Approved 2005
Inspired by bradykinin-potentiating peptides in Brazilian pit viper Bothrops jararaca venom. The first ACE inhibitor to hit the market.
Bothrops jararaca · FDA Approved 1981
Venomics AI is industrializing this logic: moving from one-off discoveries to a scalable discovery engine.
Five disease areas where venom biology offers transformative therapeutic potential.
Drug-resistant infections are outpacing the discovery of new antibiotics. Venom-derived peptides offer a rich source of molecules that can disrupt microbial membranes, modulate host defence, and reveal new antimicrobial mechanisms.
Discovering and engineering venom-derived antimicrobial candidates against resistant pathogens.
Metabolic disease is one of the largest therapeutic markets in the world. Venom-associated molecules have already contributed to incretin biology and GLP-1-based therapeutics.
Identifying molecules that regulate appetite, glucose homeostasis, insulin secretion, energy balance, and metabolic signalling.
Cellular senescence contributes to chronic inflammation, tissue dysfunction, fibrosis, cancer progression, and ageing-associated disease. Venom molecules can selectively modulate cell signalling, stress responses, survival pathways, and immune interactions.
Discovering molecules that help detect, modulate, or eliminate pathological senescent cells.
Ion channels are central to pain, neurology, cardiac function, and cellular excitability. Venoms are among the richest natural sources of ion-channel modulators, especially peptide toxins with high potency and selectivity.
Targeting voltage-gated sodium, potassium, calcium, and other ion channels for pain, neurology, and related indications.
Cancer cells depend on altered signalling, metabolism, membrane composition, immune evasion, and tumour-specific vulnerabilities. Venom-derived molecules can interact with receptors, ion channels, membranes, and tumour-associated pathways.
Developing venom-inspired molecules for tumour targeting, cytotoxicity, imaging, and precision oncology.
From raw venom to therapeutic candidate — five integrated stages of discovery.
A curated repository of animal venoms linked to species identity, geography, ecology, and biological context.
A multi-omics map connecting venom composition, toxin sequences, structure, bioactivity, and disease relevance.
A purpose-built AI system trained to infer toxin function, target selectivity, and therapeutic potential from biological data.
A growing collection of natural toxins and synthetic analogues tested against disease-relevant targets.
AI-guided engineering, pharmacology, and translational validation to convert venom molecules into drug candidates.
India is one of the world's most important venom biodiversity hotspots, but its venom-derived therapeutic potential remains largely untapped.
Venomics AI is uniquely positioned at the intersection of
Access to extraordinary venomous animal diversity across the Indian subcontinent.
Deep toxinology, evolutionary biology, venom pharmacology, and translational research experience.
Modern computational tools for sequence analysis, molecular design, target prediction, and lead prioritisation.
A region with major unmet needs in infectious disease, metabolic disease, cancer, pain, and neglected conditions.
The opportunity is to build the world's leading venom biodiscovery platform from India.
From field collection to clinical translation — an integrated set of capabilities that covers every stage of venom-derived drug discovery.
Field ecology, specimen provenance, venom collection, and biodiversity mapping.
Proteomics, transcriptomics, peptide sequencing, toxin annotation, and comparative venomics.
Machine learning for target prediction, sequence-function modelling, prioritisation, and molecule generation.
Functional screening against ion channels, receptors, enzymes, cells, and disease-relevant assays.
Peptide optimisation, antibody discovery, small-molecule discovery, and developability assessment.
Academic, clinical, biotech, pharma, and investor partnerships to move candidates toward development.
A multidisciplinary team spanning toxinology, computational biology, and machine learning.
KS
An evolutionary biologist at the Indian Institute of Science, Bengaluru, Prof. Sunagar has built one of India’s leading venom research programs. His work spans venom evolution, snakebite therapeutics, antibody discovery, small-molecule inhibitors, and the translational use of venom biology for medicine.
VP
Dr. Prabhu brings deep expertise in machine learning, large-scale AI systems, and computational biology. At Venomics AI, he leads the development of AI platforms that convert venom datasets into therapeutic insights and drug discovery programs.
Our platform builds on years of peer-reviewed research in venom biology, toxin pharmacology, and snakebite therapeutics — a selection of which is below.
Stories from Prof. Kartik Sunagar on venom biology, snakebite, evolution, and the adventures that connect them.
Key milestones, funding announcements, and press features from the Venomics AI team.
Kartik and Vinay met in India after 15 years and Venomics AI was conceptualized.
Company Milestone
Venomics AI has managed to raise $3M in funding on 10th April 2026.
Funding Announcement
Researchers at EVL successfully developed a broadly neutralizing antibody targeting conserved regions of snake venom neurotoxins.
The Hindu
Whether you're an investor, partner, scientist, or patient advocate, we want to hear from you.
Partnerships, licensing, investor conversations, media, and scientific collaborations.
No 33, 4th Floor, 1st Main, Ganganagar Gramatana, HMT, R T Nagar, Bengaluru 560032, Karnataka, India
Your email app should open with a drafted message to our team.
